Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$16.26 +0.8%	$12.76	$9.22 ▼ $21.00	$742.19M	1	820,093 shs	1.16 million shs
BBNX Beta Bionics	$18.62 -1.8%	$15.13	$8.89 ▼ $24.50	$809.41M	N/A	527,671 shs	239,934 shs
INFU InfuSystem	$10.72 +3.7%	$7.02	$4.61 ▼ $10.90	$219.68M	1.81	175,012 shs	650,916 shs
SIBN SiBone	$16.62 +0.2%	$17.01	$11.70 ▼ $20.05	$716.00M	0.91	426,917 shs	142,547 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-0.43%	+3.73%	+24.25%	+48.07%	+26.99%
BBNX Beta Bionics	+3.49%	+23.99%	+35.60%	+23.50%	+1,896,999,900.00%
INFU InfuSystem	+4.23%	+7.71%	+75.25%	+84.64%	+59.32%
SIBN SiBone	+1.04%	+6.76%	-5.74%	-12.59%	+0.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	2.6191 of 5 stars	3.5	2.0	0.0	3.2	1.7	0.6
BBNX Beta Bionics	1.5505 of 5 stars	3.4	0.0	0.0	2.5	0.8	0.0
INFU InfuSystem	2.5689 of 5 stars	1.0	5.0	0.0	2.5	4.2	1.9
SIBN SiBone	4.2558 of 5 stars	3.5	4.0	3.3	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$26.00	59.89% Upside
BBNX Beta Bionics	2.75	Moderate Buy	$22.56	19.34% Upside
INFU InfuSystem	4.00	Strong Buy	$12.50	16.50% Upside
SIBN SiBone	3.00	Buy	$23.67	42.70% Upside

Current Analyst Ratings Breakdown

Latest INFU, BBNX, AXGN, and SIBN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$25.00
8/5/2025	SIBN SiBone	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
7/30/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $21.00
7/30/2025	BBNX Beta Bionics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$15.00 ➝ $17.00
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/12/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$30.00
5/30/2025	BBNX Beta Bionics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$16.00
5/30/2025	BBNX Beta Bionics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$203.27M	3.68	N/A	N/A	$2.44 per share	6.66
BBNX Beta Bionics	$65.12M	12.62	N/A	N/A	$6.94 per share	2.72
INFU InfuSystem	$139.89M	1.57	$0.84 per share	12.79	$2.47 per share	4.34
SIBN SiBone	$167.18M	4.28	N/A	N/A	$3.95 per share	4.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$9.96M	-$0.10	N/A	N/A	N/A	-2.29%	-4.43%	-2.34%	11/6/2025 (Estimated)
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	$870K	$0.23	178.28	34.61	N/A	1.12%	2.78%	1.41%	N/A
SIBN SiBone	-$30.91M	-$0.56	N/A	N/A	N/A	-12.83%	-14.20%	-10.38%	11/11/2025 (Estimated)

Latest INFU, BBNX, AXGN, and SIBN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/4/2025	Q2 2025	SIBN SiBone	-$0.19	-$0.14	+$0.05	-$0.14	$48.12 million	$48.63 million
7/29/2025	Q2 2025	BBNX Beta Bionics	-$0.51	-$0.39	+$0.12	-$0.39	$19.73 million	$23.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.59	4.14	2.67
BBNX Beta Bionics	N/A	14.68	13.79
INFU InfuSystem	0.50	1.98	1.59
SIBN SiBone	0.21	8.38	7.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
BBNX Beta Bionics	N/A
INFU InfuSystem	71.13%
SIBN SiBone	98.11%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
BBNX Beta Bionics	N/A
INFU InfuSystem	11.40%
SIBN SiBone	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	46.01 million	44.73 million	Optionable
BBNX Beta Bionics	294	43.47 million	N/A	N/A
INFU InfuSystem	410	20.43 million	19.10 million	Optionable
SIBN SiBone	350	43.14 million	41.42 million	Optionable

INFU, BBNX, AXGN, and SIBN Headlines

Recent News About These Companies

AlphaQuest LLC Purchases 25,764 Shares of SiBone $SIBN

August 28 at 5:35 AM | marketbeat.com

Russell Investments Group Ltd. Has $2.83 Million Stake in SiBone $SIBN

August 27 at 3:38 AM | marketbeat.com

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025

August 26 at 4:03 PM | globenewswire.com

American Century Companies Inc. Purchases 264,254 Shares of SiBone $SIBN

August 23, 2025 | marketbeat.com

1,326,100 Shares in SiBone $SIBN Acquired by Nuveen LLC

August 22, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in Stock

August 21, 2025 | insidertrades.com

Tocqueville Asset Management L.P. Has $3.58 Million Stake in SiBone (NASDAQ:SIBN)

August 19, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Director John Gordon Freund Sells 12,132 Shares

August 12, 2025 | marketbeat.com

Insider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of Stock

August 12, 2025 | insidertrades.com

SiBone (NASDAQ:SIBN) Stock Rating Lowered by Wall Street Zen

August 10, 2025 | marketbeat.com

FY2025 EPS Estimates for SiBone Boosted by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Shares Down 13.1% - Here's What Happened

August 6, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Earns "Overweight" Rating from Cantor Fitzgerald

August 6, 2025 | marketbeat.com

SiBone (NASDAQ:SIBN) Issues Quarterly Earnings Results

August 5, 2025 | marketbeat.com

SI-Bone Reports Strong Q2 2025 Financial Results

August 5, 2025 | msn.com

SI-BONE, Inc. (SIBN) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

SI-BONE, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 4, 2025 | seekingalpha.com

Si-Bone (SIBN) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2025 | zacks.com

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance

August 4, 2025 | globenewswire.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in SiBone (NASDAQ:SIBN)

August 3, 2025 | marketbeat.com

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025

July 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INFU, BBNX, AXGN, and SIBN Company Descriptions

AxoGen NASDAQ:AXGN

$16.26 +0.12 (+0.77%)

As of 03:52 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Beta Bionics NASDAQ:BBNX

$18.62 -0.35 (-1.85%)

As of 03:33 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

InfuSystem NYSE:INFU

$10.72 +0.38 (+3.68%)

As of 03:52 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

SiBone NASDAQ:SIBN

$16.62 +0.03 (+0.20%)

As of 03:52 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time